343952-87-4

Basic information

• Product Name: 4-bromo-N2-phenyl-1,2-benzenediamine
• Synonyms: 4-bromo-N2-phenyl-1,2-benzenediamine
• CAS NO: 343952-87-4
• Molecular Weight: 263.137
• Mol File: 343952-87-4.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-bromo-N2-phenyl-1,2-benzenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N2-phenyl-1,2-benzenediamine(343952-87-4)
• EPA Substance Registry System: 4-bromo-N2-phenyl-1,2-benzenediamine(343952-87-4)

Safety Data

• Hazardous Substances Data: 343952-87-4(Hazardous Substances Data)

Upstream product

• 6311-47-3 N-(5-bromo-2-nitrophenyl)benzenamine 
• 4418-84-2 4-bromoazobenzene 
• 64-17-5 ethanol 
• 610-38-8 4-bromo-1,2-dinitrobenzene 
• 62-53-3 aniline 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 96048-75-8 6-bromo-1-phenyl-1H-benzo[d]imidazole 
• 1616096-79-7 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(1-phenyl-1H-benzo[d]imidazol-6-yl)phenoxy)propan-2-ol 
• 1103917-89-0 6-bromo-1,2-diphenyl-1H-benzo[d]imidazole 
• 79759-43-6 5-bromo-1-methyl-3-phenyl-1,3-dihydro-benzoimidazol-2-one 
• 79759-42-5 6-bromo-1-phenyl-1H-benzo[d]imidazol-2(3H)-one 
• 79759-16-3 (4-Bromo-2-phenylamino-phenyl)-carbamic acid ethyl ester 

Relevant articles and documents

Benzimidazolone derivatives organic light emitting compound and organic electroluminescent device including the same

Provided is a benzo imidazolone derivative organic electroluminescent compound represented by chemical formula a. Chemical Formula a. The benzo imidazolone derivative organic light emitting compound is suitable for inclusion in an organic electroluminescent device. Both electrochemical stability and thermal stability can be satisfactorily met.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.